SCHEMBL1124071

SCHEMBL1124071

COc1ccc(C=Cc2nc(N3CCOCC3)c(N)c(N(C)C(N)=O)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
MCHR1 Q99705 1/20 0.39
HTT P42858 1/20 0.39
PIK3CA P42336 1/20 0.39
FLT3 P36888 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
RXFP1 Q9HBX9 2/20 0.39
PTGS2 P35354 1/20 0.38
NOS1 P29475 1/20 0.38
ENPP1 P22413 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
AKR1C3 P42330 1/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1123841 0.88 FLT3 (0.42) MAPTKDM4ENPC1PKMRAB9A
SCHEMBL1124048 0.88 FLT3 (0.42) MAPTKDM4ENPC1PKMRAB9A
SCHEMBL1123926 0.85 FLT3 (0.47) MAPTKDM4ENPC1PKMRAB9A
SCHEMBL1123930 0.85 FLT3 (0.47) MAPTKDM4ENPC1PKMRAB9A
SCHEMBL1123916 0.82 FLT3 (0.45) MAPTKDM4ENPC1RAB9APIK3CA
SCHEMBL1123917 0.82 FLT3 (0.45) MAPTKDM4ENPC1RAB9APIK3CA
SCHEMBL1123971 0.81 PIK3CA (0.43) MAPTKDM4EPIK3CAFLT3MEN1
SCHEMBL1123970 0.81 PIK3CA (0.43) MAPTKDM4EPIK3CAFLT3MEN1
SCHEMBL1123803 0.81 FLT3 (0.39) MAPTKDM4ENPC1RAB9APIK3CA
SCHEMBL1123800 0.81 FLT3 (0.39) MAPTKDM4ENPC1RAB9APIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563715-B2 Pyrimidine derivative having cell protecting effect and uses thereof ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2013-10-22 US claimed
US-20110152519-A1 PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-06-23 US claimed
EP-2284160-A1 PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-02-16 EP claimed
US-8563715-B2 Pyrimidine derivative having cell protecting effect and uses thereof ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2013-10-22 US disclosed
EP-2284160-B1 PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF ZENYAKU KOGYO KK (JP) 2013-05-15 EP disclosed
US-20110152519-A1 PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-06-23 US disclosed
EP-2284160-A1 PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2011-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152519-A1 PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF CASP3, DPYD, CASP1 MAPT 350/4885KDM4E 4265/4885NPC1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.